Recent investigations have converged on the convergence of GLP|GIP|glucagon receptor agonist therapies and DA communication. While GCGR activators are increasingly employed for addressing type 2 diabetes, their potential consequences on reinforcement circuits, specifically mediated by dopamine networks, are gaining substantial interest. This articl